Loading...

CELC CELCUITY INC Expansion Plans 8-K Filing

CLCT

CLC

CELCUITY INC

(CELC)

2026 8-K

Board Expansion

Stockholder Approvals

Financial Results

Positive Trial Results

Financial Results Report

Board Appointment

FDA Application Submitted

Financial Results Release

Clinical Trial Results

Loan Agreement Update

Quarterly Earnings Report

Equity Offerings

Equity Offerings

Debt-Equity Swaps

Market Expansion

Contract Renewal

Financial Statements

Financial Results

Q3 Financial Results

Q2 Financial Results

Underwriting Agreement

Loan Agreement for Phase 3 ...

Earnings Report

Annual Meeting and Plan Ame...

Loan Agreement Amendment

Earnings Release

Investment Disposal

Earnings Reports

Private Placement

Compensation Program Update

Clinical Trial and Collabor...

Financial Results for Q2 2023

Financial Results

Annual Meeting Approval

Earnings Report

Lease Amendment

Deposit Account with Silico...

External Links:

Celcuity Inc. reported positive results from the VIKTORIA-1 clinical trial for gedatolisib on May 1, 2026, showing significant improvement in progression-free survival in patients with advanced breast cancer compared to existing treatment. The company plans to submit these findings to the FDA and present them at the 2026 ASCO Annual Meeting.

AI Assistant

CELCUITY INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.